Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan effect on metformin pharmacokinetics in healthy volunteers
NCT07121959Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belzutifan (2 arms), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity for Metformin in Plasma at 48 hours. Started Aug 2025; status: completed.
02
Drugs
belzutifan
Beyond the preview
Go deeper on NCT07121959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121959.